Phase I, Single-centre, Randomised, Placebo-controlled, Double-blinded Study, With Single Ascending Dose and Multiple Dose at Maximum Tolerated Dose, Evaluating the Safety, Tolerability and Pharmacokinetics of ALX-0171, Administered by Pulmonary Inhalation, in Healthy Male Volunteers.

Trial Profile

Phase I, Single-centre, Randomised, Placebo-controlled, Double-blinded Study, With Single Ascending Dose and Multiple Dose at Maximum Tolerated Dose, Evaluating the Safety, Tolerability and Pharmacokinetics of ALX-0171, Administered by Pulmonary Inhalation, in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2012

At a glance

  • Drugs ALX 0171 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Sep 2012 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Status changed from not yet recruiting to recruiting, according to an Ablynx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top